New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 4, 2013
08:36 EDTOMEDOncoMed initiates third Phase 1b combination clinical trial of vantictumab
OncoMed Pharmaceuticals announced that it has started a Phase 1b clinical trial of its first-in-class Wnt-pathway-targeting antibody vantictumab in combination with nab-paclitaxel and gemcitabine in patients with Stage IV pancreatic cancer. This trial is the third of three Phase 1b trials for vantictumab initiated this year as part of OncoMed's collaboration with Bayer Pharma AG. The multi-center Phase 1b clinical trial is a dose escalation study that will evaluate safety of vantictumab in combination with Abraxane and gemcitabine and determine a recommended Phase 2 dose for this combination regimen. Key secondary and exploratory objectives include evaluation of the pharmacokinetics of vantictumab, as well as the pharmacodynamics and efficacy of this combination. Tumor tissue from patients will be used to explore predictive biomarker hypotheses related to the efficacy of vantictumab.
News For OMED From The Last 14 Days
Check below for free stories on OMED the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for OMED

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use